Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on DFMO Intermediate. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN113072456A details a novel copper-catalyzed asymmetric difluoromethylation for high-purity pharmaceutical intermediates, offering significant cost and supply chain advantages.